Advanced Imaging Within the Bile Duct During Endoscopic Retrograde Cholangiopancreatography

Sharzehi, Kaveh; Coté, Gregory A.

doi:10.1016/j.cgh.2021.12.006

Cited by 1 publication

(2 citation statements)

References 8 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…114,115 The sensitivity of intraductal imaging in detecting malignancy is greater than cholangioscopy-directed intraductal biopsies but its specificity remains inferior to the gold-standard cytopathology. 116 The role of DSOC has become integral in the evaluation of biliary strictures and is considered the modality of choice for evaluation of proximal bile duct strictures. 117 The development of EUS with fine-needle aspiration (FNA) further improved the diagnostic capacity of EUS.…”

Section: Cholangioscopymentioning

confidence: 99%

“…Although no formal consensus has been established on specific diagnostic criteria, nodular or papillary masses, irregular surface, fragile mucosa, and tortuous dilated vessels are typical for neoplasia with sensitivities and specificities ranging from 90% to 100% and 75% to 95%, respectively 114,115 . The sensitivity of intraductal imaging in detecting malignancy is greater than cholangioscopy‐directed intraductal biopsies but its specificity remains inferior to the gold‐standard cytopathology 116 . The role of DSOC has become integral in the evaluation of biliary strictures and is considered the modality of choice for evaluation of proximal bile duct strictures 117 .…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

The multidisciplinary management of cholangiocarcinoma

Ohaegbulam

Koethe

Fung

et al. 2022

Cancer

Self Cite

View full text Add to dashboard Cite

Cholangiocarcinoma is a lethal malignancy of the biliary epithelium that can arise anywhere along the biliary tract. Surgical resection confers the greatest likelihood of long‐term survivability. However, its insidious onset, difficult diagnostics, and resultant advanced presentation render the majority of patients unresectable, highlighting the importance of early detection with novel biomarkers. Developing liver‐directed therapies and emerging targeted therapeutics may offer improved survivability for patients with unresectable or advanced disease. In this article, the authors review the current multidisciplinary standards of care in resectable and unresectable cholangiocarcinoma, with an emphasis on novel biomarkers for early detection and nonsurgical locoregional therapy options.

show abstract